Clinical Results With Phenelzine

Saunders, John C.; Roukema, Richard W.; Kline, Nathan S.; Bailey, Samuel d'A.

doi:10.1176/ajp.116.1.71

Cited by 10 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A comprehensive literature search of Google Scholar and PubMed revealed that the first phenelzine studies were published in 1959 4. There have been no documented cases of L-tyrosine-associated hypertensive crisis.…”

Section: Resultsmentioning

confidence: 99%

“…There have been no documented cases of L-tyrosine-associated hypertensive crisis. Conversely, several articles were found illustrating that when normal blood pressure exists or the subject is hypertensive, L-tyrosine lowers blood pressure 4–12. The assertion that ingestion of L-tyrosine with phenelzine induces hypertensive crisis is without scientific literature verification.…”

Section: Resultsmentioning

confidence: 99%

“…The most reliable safety (side effect) data are collected over time through prescribing to large populations. The earliest peer-reviewed literature located discussing phenelzine, by Saunders et al,4 was published on 1 July 1959. Phenelzine has been prescribed for 55 years.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Administration of supplemental L-tyrosine with phenelzine: a clinical literature review

Hinz¹,

Stein²,

Cole³

et al. 2014

CPAA

View full text Add to dashboard Cite

The subject of this literature review is the alleged relationship between L-tyrosine, phenelzine, and hypertensive crisis. Phenelzine (Nardil®) prescribing information notes: “The potentiation of sympathomimetic substances and related compounds by MAO inhibitors may result in hypertensive crises (see WARNINGS). Therefore, patients being treated with NARDIL should not take […] L-tyrosine […]”. Interest in the scientific foundation of this claim was generated during routine patient care. A comprehensive literature search of Google Scholar and PubMed revealed no reported cases of hypertensive crisis associated with concomitant administration of L-tyrosine and phenelzine. Review of current US Food and Drug Administration nutritional guidelines relating to ongoing phenelzine studies reveals no mention and requires no consideration of L-tyrosine ingestion in combination with phenelzine. This paper is intended to provide an objective review of the science to then allow the reader to formulate the final opinion.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Administration of supplemental L-tyrosine with phenelzine: a clinical literature review

Hinz¹,

Stein²,

Cole³

et al. 2014

CPAA

View full text Add to dashboard Cite

show abstract

“…Other hydrazine inhibitors were subsequently developed and include isocarboxazide (Marplan) (Heinrich & Petrilowitch, 1960;Larsen & Rafaelsen, 1980) and phenelzine (Nardil) (Saunders, Roukema, Kline, & Bailey, 1959;Furst, 1959). More than ten other hydrazine MAO inhibitors, including benmoxin (Neuralex, Nerusil), iproclozide (Sursum), mebanazine (Actomol), niamid (Nialamide), octamoxin (Ximaol/Nimaol), pheniprazine (Cantron), phenoxypropazine (Drazine), pivalylbenzhydrazine or pivhydrazine (Tresavid), and safrazine (Safra), have been either withdrawn from the market or were never registered for commercialization, mostly because of hepatotoxicity.…”

Section: Irreversible Non-selective Mao Inhibitorsmentioning

confidence: 99%

Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle

Entzeroth¹,

Ratty²

2017

OJD

View full text Add to dashboard Cite

Over more than 60 years, monoamine oxidase (MAO) inhibitors are available for therapy of central nervous diseases. Although they have shown to be efficacious specifically in the treatment of major depressive disorders and treatment-resistant depression, they became less a therapeutic choice for the physicians mostly due to severe side effects, such as liver failure and hypertensive crisis associated specifically with the first generation of inhibitors. Nevertheless, this class of drugs is still being used for treatment specifically as more selective and reversible inhibitors became available and will provide clinicians with additional treatment options. The current review revisits monoamine oxidase inhibitors and their potential in the treatment of human diseases, such as anxiety, depression, mood and personality disorders, and pain and introduces current ideas and developments.

show abstract

Drugs of Choice for the Emotionally Ill Office Patient

Smith¹

1965

JAMA

View full text Add to dashboard Cite

Clinical Results With Phenelzine

Cited by 10 publications

References 1 publication

Administration of supplemental L-tyrosine with phenelzine: a clinical literature review

Administration of supplemental L-tyrosine with phenelzine: a clinical literature review

Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle

Drugs of Choice for the Emotionally Ill Office Patient

Contact Info

Product

Resources

About